Nippon India PHARMA Fund - G

NAV ₹559.852 ↓ -9.61 (-1.69 %) as on 30 Sep 26

📑 Table of contents

Scheme Objective
NAV Price Chart
Returns
- Historical Returns
- Compounded Returns
Growth Of 10k Over Years
Holdings / Portfolio
All Plan & Options
Fund Manager Information
Custodians
Registrar & Transfer Agent (RTA)
Administrator Companies
Auditors

Scheme Objective

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Nippon India Pharma Fund is a Equity - Sectoral fund launched on 5 Jun 04. It is a fund with High risk and has given a CAGR return of 19.8% since its launch. Ranked 35 in Sectoral category. Return for 2025 was -3.3% , 2024 was 34% and 2023 was 39.2% .

Below is the key information for Nippon India Pharma Fund

NAV as on 30 Sep 26	₹559.852 ↓ -9.61 (-1.69 %)
Net Assets (AUM) as on 31 Aug 2026	₹9,479 Cr.
Launch Date	5 Jun 2004
Category	Equity - Sectoral
Rating	☆☆
Type	Open Ended Fund
Risk	High
AMC	Nippon Life Asset Management Ltd.

Alpha Ratio	-2.25
Expense Ratio	1.81 %
Sharpe Ratio	0.683
Information Ratio	-1.16
Benchmark	Not Available
Min Investment	₹5,000
Min SIP Investment	₹100
Exit Load	0-1 Years (1%),1 Years and above(NIL)

NAV Price Chart

Returns

Annual Compounded Returns

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 30 Sep 26

Duration	Returns
1 Month	-3.6%
3 Month	0.4%
6 Month	14.3%
1 Year	12.9%
3 Year	16.7%
5 Year	12.7%
10 Year
15 Year
Since launch	19.8%

Historical Annual Returns

Historical performance (Yearly) on absolute basis

Year	Returns
2024	-3.3%
2023	34%
2022	39.2%
2021	-9.9%
2020	23.9%
2019	66.4%
2018	1.7%
2017	3.6%
2016	7.6%

Growth of 10k Over Years

Date	Value
30 Sep 21	₹10,000
30 Sep 22	₹9,173
30 Sep 23	₹11,457
30 Sep 24	₹16,998
30 Sep 25	₹16,124

Asset Allocation

Asset Class	Value
Cash	2%
Equity	98%

Sector Allocation

Sector	Value
Health Care	98%

Top Securities Holdings / Portfolio

Holdings/Securities

Name	Global Industry	Holding	Value	Quantity
Sun Pharmaceuticals Industries Ltd (Healthcare) Equity, Since 31 Oct 09 \| SUNPHARMA	Drug Manufacturers - Specialty & Generic	12%	₹1,172 Cr	5,906,349 ↓ -300,000
Divi's Laboratories Ltd (Healthcare) Equity, Since 31 Mar 12 \| DIVISLAB	Drug Manufacturers - Specialty & Generic	7%	₹663 Cr	700,754 ↓ -50,000
Lupin Ltd (Healthcare) Equity, Since 31 Aug 08 \| 500257	Drug Manufacturers - Specialty & Generic	6%	₹609 Cr	2,783,991
Cipla Ltd (Healthcare) Equity, Since 31 May 08 \| 500087	Drug Manufacturers - Specialty & Generic	6%	₹577 Cr	4,095,054 ↑ 300,000
Apollo Hospitals Enterprise Ltd (Healthcare) Equity, Since 30 Sep 20 \| APOLLOHOSP	Medical Care Facilities	5%	₹488 Cr	548,795
Dr Reddy's Laboratories Ltd (Healthcare) Equity, Since 30 Jun 11 \| DRREDDY	Drug Manufacturers - Specialty & Generic	5%	₹468 Cr	4,049,746
Mankind Pharma Ltd (Healthcare) Equity, Since 30 Apr 23 \| MANKIND	Drug Manufacturers - Specialty & Generic	4%	₹388 Cr	1,603,562 ↑ 199,133
Sai Life Sciences Ltd (Healthcare) Equity, Since 31 Dec 24 \| SAILIFE	Diagnostics & Research	4%	₹373 Cr	2,555,745
Ajanta Pharma Ltd (Healthcare) Equity, Since 30 Apr 22 \| 532331	Drug Manufacturers - Specialty & Generic	3%	₹329 Cr	913,918
GlaxoSmithKline Pharmaceuticals Ltd (Healthcare) Equity, Since 31 Aug 22 \| GLAXO	Drug Manufacturers - General	3%	₹314 Cr	1,029,460 ↑ 100,619

1 - 10 of 40

Ready to Invest?
Talk to our investment specialist

Fund Managers

Name	Since	Tenure
Sailesh Raj Bhan	1 Apr 05	21.43 Yr.
Kinjal Desai	25 May 18	8.28 Yr.
Amber Singhania	11 Mar 26	0.48 Yr.

Custodians

Company	Address
Deutsche Bank AG	1 Great Winchester Street

Registrar & Transfer Agent

KFin Technologies Ltd
Address	138 -Suyesh Solitaire, Nr. Podar International School,Kudasan, Gandhinagar, Gujarat
FAX	N.A
Email	N.A

Administrator Companies

Company	Address
Nippon India Mutual Fund	9th Floor, Crescenzo, C-38 & 39,,G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400051

Auditors

Company	Address
Haribhakti & Co. Chartered Accountants	42, Free Press House,4th Floor,,215, Nariman Point,

All Plan & Options

Fund and Plan	NAV	6 Month	1 Year	3 Year	5 Year
Nippon India Pharma Fund Normal Dividend, Payout	₹120.897 ↓ -2.08	14.32 %	12.25 %	15.86 %	13.21 %
Nippon India Pharma Fund Normal Dividend, Reinvestment	₹120.897 ↓ -2.08	14.32 %	12.25 %	15.86 %	13.21 %
Nippon India Pharma Fund Growth	₹559.852 ↓ -9.61	14.32 %	12.88 %	16.68 %	12.72 %
Data as on 30 Sep 26

Disclaimer:
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data.

Shepard Technologies Pvt. Ltd : 1808, Solus, Hiranandani Estate, Thane, Maharashtra - 400607

AMFI Registration No. 112358 | CIN: U74999MH2016PTC282153

Mutual fund investments are subject to market risks. Please read the scheme information and other related documents carefully before investing. Past performance is not indicative of future returns. Please consider your specific investment requirements before choosing a fund, or designing a portfolio that suits your needs.

Shepard Technologies Pvt. Ltd. (with ARN code 112358) makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Terms and conditions of the website are applicable.